Please login to the form below

Not currently logged in
Email:
Password:

cell cancer

This page shows the latest cell cancer news and features for those working in and with pharma, biotech and healthcare.

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

further undermining hopes of a challenge to Merck &Co’s Keytruda in first-line non-small cell lung cancer (NSCLC). ... from this trial to gain further insights to improve immuno-oncology approaches for patients with metastatic non-small cell lung cancer

Latest news

More from news
Approximately 1 fully matching, plus 717 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    patient.”. Althoff cites Novartis’ Kymriah (tisagenlecleucel), a blood cancer cell therapy approved in Europe and the US last year, as an example of the differing manufacturing costs. ... As a result, Lonza’s efforts to reduce cell and gene therapy

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of

  • China’s clinical trial shake-up China’s clinical trial shake-up

    For example, around 40% of new lung cancer diagnoses worldwide are in China. ... Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

  • Is China ready for a pharmaceutical gold rush?

    Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    Cancers by their very nature are unique. The huge range of potential causes of the abnormal cell division that characterises cancer mean that every tumour is different. ... Drug development is outpacing our capacity to develop biomarkers due to the

More from intelligence
Approximately 0 fully matching, plus 38 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics